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Abstract
In recent years, cellular senescence has become the focus of attention in multiple areas of biomedical research. Typically 
defined as an irreversible cell cycle arrest accompanied by increased cellular growth, metabolic activity and by a charac-
teristic messaging secretome, cellular senescence can impact on multiple physiological and pathological processes such as 
wound healing, fibrosis, cancer and ageing. These unjustly called ‘zombie cells’ are indeed a rich source of opportunities for 
innovative therapeutic development. In this review, we collate the current understanding of the process of cellular senescence 
and its two-faced nature, i.e. beneficial/detrimental, and reason this duality is linked to contextual aspects. We propose the 
senescence programme as an endogenous pro-resolving mechanism that may lead to sustained inflammation and damage 
when dysregulated or when senescent cells are not cleared efficiently. This pro-resolving model reconciles the paradoxical 
two faces of senescence by emphasising that it is the unsuccessful completion of the programme, and not senescence itself, 
what leads to pathology. Thus, pro-senescence therapies under the right context, may favour inflammation resolution. We 
also review the evidence for the multiple therapeutic approaches under development based on senescence, including its 
induction, prevention, clearance and the use of senolytic and senomorphic drugs. In particular, we highlight the importance 
of the immune system in the favourable outcome of senescence and the implications of an inefficient immune surveillance 
in completion of the senescent cycle. Finally, we identify and discuss a number of challenges and existing gaps to encourage 
and stimulate further research in this exciting and unravelled field, with the hope of promoting and accelerating the clinical 
success of senescence-based therapies.
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Introduction, definitions and history
Senescence, /sɪˈnɛs(ə)ns/, noun—the condition or process of 
deterioration with age
Dating back to the seventeenth century, the term senes-
cence was used to refer to the general and gradual accu-
mulation of changes over time leading to the decline of 
organismal function, essentially aging. In this context, this 
process is now referred to as organismal senescence. Senes-
cence also applies to plants, appreciable during autumn when 
chlorophyll is recycled revealing the bright red leaf colour of 
carotenoids, and to unicellular organisms like bacteria when 
they exhibit decreased growth rate [1]. However, the type of 
senescence, subject of this review, that has recently captured 
the attention of the scientific community, pharmaceutical 
industry and even the general public is known as cellular 
senescence, typically defined as the irreversible or stable cell 
cycle arrest even in the presence of mitogenic stimuli [2, 3]. 
This rather simple definition encompasses a very complex 
and highly heterogeneous phenomenon, in which the stable 
cell cycle arrest can be driven by multiple mechanisms and 
associated with diverse phenotypes and functions. Together 
with loss of proliferative potential, a key feature that distin-
guishes senescence from other arrested cellular states, such 
as quiescence or terminal differentiation, is the acquisition of 
the ‘senescence-associated secretory phenotype’ (SASP) [4], 
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which has strong implications on the outcome of senescence 
and in the development of therapeutic interventions.
The discovery of cellular senescence in 1961 by Hayflick 
and Moorhead [5] represented a ground-breaking finding 
as it was the first demonstration that normal cells are not 
immortal, as believed at the time, and provided the basis for 
a scientific explanation of the evolutionary theory of age-
ing initiated by Peter B. Medawar in 1952. In his lecture 
‘An unresolved Problem of Biology’ delivered at University 
College London, he stated that the force of natural selection 
declines with age as the probability of an organism to exist 
declines (e.g. due to diseases, accidents, predators) in paral-
lel to its reproductive value, a concept known as selection 
shadow. Hence, gene variants that are beneficial in early 
life are favoured over genes beneficial late in life, in perfect 
agreement with Darwinian theories. George C. Williams 
built on this model and introduced in 1957 the concept of 
antagonistic pleiotropy [6], based on genes having multiple 
functions: harmful late-acting genes can remain and accu-
mulate in the population if they have a beneficial effect early 
in life. Hence, the biological and inevitable mortality of cells 
discovered by Hayflick and Moorhead fitted with Medawar 
and Williams model of ageing: cellular senescence is evo-
lutionary conserved, because it confers survival advantage 
early in life, even if, past reproduction age, manifests del-
eterious effects. The cost–benefit in evolutionary terms is 
favourable.
Forty years on, our view of cellular senescence has been 
expanded, shaken, refined and now apparently settled on the 
consensus that the actual process of senescence is necessary 
and desirable to avoid propagation of cellular damage, but 
it is the failure of timely clearing of these cells from tissues 
that leads to persistent damage, a process where the (aged) 
immune system might play a major role, as will be discussed 
later. Worth mentioning at this point is the concept of immu-
nosenescence which broadly speaking refers to the general 
and progressive decline of immune function during ageing. 
Senescence in T cells refers to the loss of proliferative poten-
tial generally resulting from excessive telomere erosion and 
associated with increased cytokine release [7]. However, it 
is not clear what immunosenescence refers to in terminally 
differentiated, hence non-proliferative, immune cells like, 
for example, neutrophils. Pears and apples are being mixed 
under the same label. Beyond a perhaps irrelevant discrep-
ancy on definitions, an immediate consequence is that mark-
ers normally used to identify and study cellular senescence 
may be unsuitable to study immunosenescence, like prolif-
eration arrest markers. Even in T cells, where senescence 
fits with the accepted definition of cellular senescence, it is 
not clear whether the typical markers p16 or β-galactosidase 
are involved [7]. Hence, a consensus of what constitutes 
immunosenescence and specific definitions applicable to 
proliferative and terminally differentiated immune cells are 
still needed.
In this review, we present senescence in the context of the 
resolution of inflammation and propose that a failure of this 
endogenous protective mechanism leads to persistent dam-
age and inflammation. We also highlight the heterogeneity of 
senescence, how this diversity impacts research and oppor-
tunities and we bring together different views, contradictory 
only in appearance, on the role of senescence in health and 
disease and why consideration of ‘context’ is determining. 
In addition, we discuss the influence of the immune system 
in the successful completion of the senescence programme 
and how senescence can be harnessed therapeutically from 
multiple angles. Finally, we raise existing knowledge gaps 
and current challenges that need to be addressed to advance 
the therapeutic exploitation of senescence, hoping to stimu-
late and encourage the field to transform patient care based 
on strategies targeting senescence in multiple therapeutic 
areas such as ageing, tissue repair and cancer.
The endogenous defensive role of cellular 
senescence
General pathways and mission of senescence
Cellular senescence is a state of permanent cell cycle arrest 
induced in proliferating cells by multiple stressors and con-
ditions. The most common mechanism involves the activa-
tion by p53 of cyclin-dependent kinase (CDK) inhibitors, 
such as p16 (CDKN2A), p15 (CDKN2B), p21 (CDKN1A) 
or p27 (CDKN1B). These inhibitors block the actions of 
CDK/cyclins complexes, preventing the phosphorylation 
of the retinoblastoma protein, Rb [3]. Hypophosphorylated 
Rb remains bound to the transcription factor E2F, prevent-
ing the transition of the cell cycle from  G1 to S phase. This 
loss of proliferative potential occurs even in the presence of 
serum or growth factors, a key difference from quiescence, 
where cells, whilst non-proliferative, retain the potential to 
proliferate again when mitogenic stimuli become available 
[8]. Quiescence is an exit from the cell cycle into  G0, while 
senescence is an arrest in  G1. This implies another key dis-
tinctive feature of senescent cells: although proliferation is 
halted, growth is still ongoing, reflected in the increase in 
cell size, lysosomes and metabolic activity, all hallmarks 
of cellular senescence [2, 9, 10]. Quiescence is a stand-by 
mode, while senescence is a flight forward.
The increased activity of senescent cells results in a char-
acteristic messaging secretome, the SASP, that confers new 
functions to the senescent cells. This is an important differ-
ence with apoptosis. Although both processes seem to share 
the mission of eliminating damaged cells and limit the prop-
agation of the damage to daughter cells, it is not completely 
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clear what determines one fate or another. Some redundancy 
exists, as there is evidence that one can compensate, to some 
extent, for the absence of the other [11]. Apoptosis is per se 
a cell death mechanism, but senescent cells remain alive for 
long periods of time [12], as if they could still offer a last 
service to the host before ultimately being eliminated. This 
last service is offered by the SASP [13, 14], a combina-
tion of factors that initiate the tissue repair programme and 
attract the immune system to induce their own clearance. 
The SASP also amplifies the senescence process by induc-
ing secondary senescence to neighbouring cells either via 
soluble factors [15, 16] or via extracellular vesicles [17] and 
contributes to their increased survival. Moreover, the SASP 
can also promote a pro-regenerative response by favouring 
cell plasticity and stem cell activity [18] and induce vascular 
remodelling [19].
In summary, both arms of senescence, proliferation arrest 
and secretome, play specific homeostatic and defensive 
roles in physiological and pathological situations. This is 
discussed next.
Cancer, tissue repair and development
The first type of senescence discovered by Hayflick and 
Moorhead [5], now referred to replicative senescence, is 
caused by the progressive shortening of telomeres after a 
limited number of cell divisions resulting in the activation 
of the DNA damage response (DDR) once a critical telomere 
length has been reached. This response leads to senescence, 
preventing proliferation of aberrant cells and inhibiting 
tumour formation [20]. Similarly, the DDR can be triggered 
by the acquisition of activating or inactivating mutations in 
oncogenes or tumour suppressor genes, respectively, lead-
ing to the activation of mainly p53 and p16 or p21, initiat-
ing the senescence programme [3]. This oncogene-induced 
senescence was first discovered for the gene HRAS [21] and 
later on for other genes such as PTEN, MYC, BRAF, TP53, 
RAC1 and many others [22], and represents a potent endog-
enous anti-cancer mechanism acting at very early stages 
of tumorigenesis. Melanocytic nevi on skin surface are a 
visible example of oncogene-induced senescence, in which 
BRAF is mutated in ~ 80% of the cases [23] typically acquir-
ing the activating mutation BRAFV600E. This illustrates the 
essential protective role of senescence under the constant 
environmental oncogenic pressure exerted by UV radia-
tion. Indeed, germline mutations in CDKN2A, permitting 
senescence bypass, greatly increase melanoma susceptibility 
[24]. Inactivating mutations in other pro-senescence media-
tors like CDKN1A, associated with bladder cancer [25], or 
RB1, linked to retinoblastoma, provide further evidence of 
the anti-tumour role of senescence. In mice, mutations in 
CDKN2A gene, affecting either or both encoded proteins 
p16 and p19, or in CDKN1A, result in increased tumour 
development susceptibility [26, 27].
The senescence programme also orchestrates tissue 
remodelling associated with development as well as wound 
healing. Senescence occurs in the embryo in multiple struc-
tures like the endolymphatic sac, the inner ear, the apical 
ectodermal ridge and neural tube, and although some redun-
dancy exists with apoptosis, impaired senescence in certain 
structures can result in morphological defects [3, 11, 28]. 
Senescence is also involved in the regulation of placental 
formation and function, and a deficient senescence pro-
gramme has been associated with pregnancy complications 
like intrauterine growth restriction [29].
The role of senescence in tissue remodelling in the adult 
is also well established. Importantly, the SASP released by 
senescent cells influences the microenvironment orches-
trating the process of wound healing. Proliferating myofi-
broblasts at early stages of wound healing, are driven into 
senescence by matricellular proteins like CCN1 during 
the remodelling phase [30]. Much evidence suggests that 
senescent cells get locked in a pro-remodelling state char-
acterized by a reduction in collagen deposition and increase 
in the expression of remodelling enzymes like matrix metal-
loproteases. This characteristic pro-remodelling signature 
has been shown in transcriptomic analysis of dermal senes-
cent fibroblasts [31], in mouse models of cutaneous wound 
healing [30, 32], in hepatic stellate cells [33] and in syno-
vial fibroblasts from rheumatoid arthritis [34]. Interestingly, 
these examples represent very distinct types of senescence, 
including replicative, chemically induced and  MC1 agonist-
mediated senescence, suggesting that the pro-remodelling 
phenotype may be a common feature of senescence. Fur-
thermore, repair can be impaired by the active elimination of 
senescent cells, using either the p16-3MR mouse model [32] 
or administration of senolytics [34]. Physiological pre-pro-
grammed cellular senescence in the adult also occurs during 
thymic involution [35] and megakaryocyte maturation [36].
Senescence as a pro‑resolving mechanism
The termination of the inflammatory response is achieved by 
a number of endogenous mediators that promote the active 
and safe completion of the inflammatory response leading 
to restoration of homeostasis. The realization of the active, 
rather than passive nature of this process, gave birth to a new 
field of research, the resolution of inflammation [37], and 
to a new strategy to target inflammatory conditions, resolu-
tion pharmacology [38], based on promoting and reinforcing 
those endogenous pathways and mediators. Another impor-
tant insight was the realisation that chronic inflammation can 
derive from the actual failure of these endogenous pathways. 
Conditions such as rheumatoid arthritis [39], atherosclerosis 
[40] and inflammatory bowel disease [41] are now seen as 
 C. S. A. Davan-Wetton et al.
1 3
a failure of resolution and among the pro-resolving path-
ways and mediators under pre- and clinical investigation are 
melanocortins [42], formyl-peptide receptors [43] and lipid 
resolvins [44].
A common feature of non-resolving inflammation is the 
dysregulated persistence of certain cells after the inflam-
matory insult has been neutralized, cells that keep dancing 
when the music has already stopped. Persistence of myofi-
broblasts that refuse to die by evading apoptosis impairs 
wound resolution by promoting fibrosis [45]. Persistence of 
activated neutrophils with increased lifespan or impaired 
clearance can delay resolution by causing excessive tissue 
damage [46]. Similarly, persistence of senescent cells pre-
vents resolution by the influence of damaging SASP. Persis-
tent myofibroblasts can be targeted with pro-apoptotic drugs 
like ABT-263 [47], similar to persistent neutrophils which 
can be eliminated with CDK inhibitors like R-roscovitine 
[46]. Hence, persistent senescent cells can similarly be tar-
geted for elimination to induce resolution.
One of the major processes that drives resolution is the 
effective and timely elimination of apoptotic immune cells 
once they have completed the function for which they were 
recruited to the tissue. Consequently, the process of effe-
rocytosis [48], or phagocytosis of apoptotic cells, is com-
monly used as a functional assay to assess the potential of 
new pro-resolving candidate molecules. Efferocytosis is 
crucial to achieve resolution because non-cleared apoptotic 
cells will turn necrotic, releasing damaging contents which 
further promote inflammation [48, 49] (Fig. 1). Similarly, 
senescence seems to follow a cycle of sensing a harmful 
stimulus followed by containment and elimination, a catch-
it-bin-it-kill-it model (Fig. 2). For many years, it has been 
debated whether in certain circumstances, like in ageing, the 
process of senescence was per se detrimental, quite in line 
with the antagonistic pleiotropy model [6], suggesting the 
existence of late-acting harmful genes. There is now sub-
stantial evidence stating that senescence may always favour 
a protective role but it is the inefficiency of the immune 
system what reveals the dark face of senescence [50, 51]. 
An inefficient coupling of the immune system to complete 
the senescence programme and close the cycle allows the 
persistence of senescent cells in tissues for long periods of 
time while releasing pro-inflammatory factors that promote 
chronic inflammation and damage (Fig. 1). The reasons why 
this clearance may fail will be discussed in detail.
We propose here that the process of cellular senescence 
represents another endogenous protective pro-resolving 
mechanism that when dysregulated, it leads to persistent 
inflammation and sustained damage, and similarly to other 
pro-resolving mechanisms, it can be targeted to favour 
resolution. We recently demonstrated that the activation of 
the pro-resolving melanocortin receptor 1  (MC1) induced 
Fig. 1  Cell clearance and the 
resolution of inflammation. a 
The resolution of inflammation 
requires the efficient and timely 
clearance of apoptotic cells 
from tissues by efferocytosis. A 
defective clearance may lead to 
secondary necrosis further pro-
moting inflammation. b Simi-
larly, the clearance of senescent 
cells, efficient and timely, is also 
required to complete the senes-
cence programme successfully. 
An impaired clearance will lead 
to persistent action of SASP 
components leading to a failure 
of resolution
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senescence in hyperactivated synovial fibroblasts from 
rheumatoid arthritis (RA) patients and favoured resolution 
of inflammatory arthritis in a serum-transfer mouse model 
[34]. RA is characterized by persistent inflammation in syno-
vial joints, in which fibroblasts play a crucial role in the 
chronicity of the process [39]. Synovial fibroblasts present 
features of tumour-like cells including excessive prolifera-
tion and invasiveness of surrounding tissues. Although non-
malignant, somatic mutations in tumour suppressor genes 
can be found, which have been shown to be epigenetically 
transformed into a permanent state of activation [52]. This 
imprinted aggressive behaviour not only sustains the pro-
inflammatory microenvironment, but it is also responsible 
for the destruction of cartilage and bone within the joints. 
Thus, induction of senescence in these cells by activating the 
pro-resolving receptor  MC1 can stop the cycle of reciprocal 
activation and favour resolution of inflammation [34].
This pro-resolving model of senescence provides a 
framework that solves the paradoxical co-existence of 
physiological and pathological consequences of senescence, 
and provides a much clearer view on why, when and how, 
senescent cells should be targeted. A failure to complete the 
programme that brings tissues back to homeostasis after a 
previous insult is what determines the detrimental effects of 
senescence, something largely determined by the context, 
as explained below.
The bright and dark sides of senescence: 
reconciling opposite views
Senescence in context
Scientific literature contains as much evidence for the protec-
tive actions of senescence as for its detrimental role (Fig. 3). 
In addition to cancer prevention and treatment, promotion 
of wound healing and embryogenesis, beneficial effects of 
senescence have been observed in liver [33, 53], renal [54] 
and skin [30] fibrosis, myocardial infarct [55], pulmonary 
hypertension [56], nerve regeneration [57], metabolic dys-
function[58], atherosclerosis, and rheumatoid arthritis [34, 
59]. On the other hand, senescence may worsen interverte-
bral disc regeneration [60], fibrotic pulmonary disease [61], 
hepatic steatosis [62], Parkinson’s disease [63], allograft 
survival [63], muscle regeneration [64], brain function [65], 
Fig. 2  The purpose of senescence. Cellular senescence is initiated 
upon detection of cellular damage or stress. The damage is contained 
by preventing spread to daughter cells and finally cleared by eliminat-
ing damaged cells and inducing tissue repair
Fig. 3  Physiological and pathological consequences of senescence. 
Beneficial and detrimental effects of senescence have been reported, 
suggesting the implementation of both pro- and anti-senescence 
approaches depending on the context
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osteoarthritis[66], type 2 diabetes [67] and radiotherapy-
induced bone loss [68]. Paradoxically, detrimental effects 
of senescence have also been reported in myocardial infarct 
[69] and dysfunction [70], cancer progression [71], meta-
bolic dysfunction [72] and atherosclerosis [73, 74].
However, evolutionary speaking, such a conserved mech-
anism would not have evolved if it were detrimental to the 
host. Amassing the existing literature on the subject, it is 
clear that multiple factors are involved in defining the impact 
of cellular senescence. We propose the consideration of four 
main contextual aspects (cell type, cellular state, SASP type 
and ageing) that largely determine the protective or adverse 
outcome of senescence (Fig. 4). First, the cell type affected 
by senescence can define the result. For example, senescence 
occurring in hepatocytes, the parenchymal cells found in 
the liver, results in dysregulated fat deposition, leading to 
hepatic steatosis [62]. However, when senescence is induced 
in myofibroblasts or in hepatic stellate cells, which are mes-
enchymal cells involved in healing by acquiring a fibroblast-
like phenotype upon injury, the effect can be beneficial by 
limiting fibrosis [33, 53]. In myocardial infarct, senescence 
happening in the functional parenchymal cells of the heart, 
i.e. cardiomyocytes, increases mortality in mice [69], while 
if senescence occurs in cardiac fibroblasts, it promotes tis-
sue repair [55].
The cellular state is another major determinant of the out-
come of senescence. In rheumatoid arthritis, synovial fibro-
blasts are epigenetically locked in a hyperactivated state, 
sustaining immune cell recruitment and activation within 
the joints that further promotes inflammation and damage. 
This vicious cycle can be broken by inducing senescence in 
those fibroblasts, favouring the resolution of inflammation 
[34]. A different scenario takes place in osteoarthritis, in 
which senescence occurring in cartilage producing chon-
drocytes (parenchymal, indeed), is associated with cartilage 
degeneration [66].
Induction of senescence in a transformed cell is unequivo-
cally beneficial to prevent cancer at an early stage. However, 
the type of SASP -third aspect of context- released in each 
particular case can greatly influence the outcome at later 
stages of tumorigenesis. Cancer cells can evade the immune 
system by various mechanisms and cancer immunotherapy 
is based on boosting the immune system to help find and/
or destroy cancer cells. Then, the ability of the SASP to 
attract the immune system can contribute to the clearance of 
senescent tumour cells [75]. For example, CCL-5 secreted 
by senescent melanoma cells promotes the recruitment of 
tumour-infiltrating leukocytes leading to a tumour suppres-
sive environment [76]. Conversely, in other forms of cancer, 
SASP contributes to cancer progression by the release of 
factors like IL-6 and IL-1α [71] as well as by other mecha-
nisms including induction of epithelial–mesenchymal tran-
sition [77], mTOR activation[78], recruitment of immature 
myeloid cells [79], or induction of the checkpoint molecule 
PD-L1 [80]. Thus, the type of SASP plays an important role 
in favouring resolution and avoiding further tissue damage.
Beyond cancer, the frequent pro-inflammatory nature of 
the SASP is believed to be responsible for the toxic effects 
that accumulating senescent cells exert in aged organisms 
[81], which links to the fourth aspect of context, ageing. This 
was elegantly shown by Velarde et al. applying in young 
and old mice the model of mitochondrial dysfunction based 
Fig. 4  Contextual aspects 
determining senescence 
outcome. Whether the results 
of senescence are beneficial 
or pathological, this is largely 
determined by multiple aspects, 
commonly overlapping. The 
most important ones include: 
cell type, cell state, type of 
SASP released and age, which 
has a strong influence on the 
surveillance capacity of the 
immune system
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on superoxide dismutase 2 (Sod2) deficiency, which leads 
to cellular senescence. They demonstrated that Sod2 defi-
ciency, and hence increased senescence, promotes wound 
healing and epidermal reepithelization in young mice, while 
the opposite was observed in old mice [82]. The pathogenic 
effect exerted by ageing on the outcome of senescence is 
largely determined by factors like stem cell exhaustion [83] 
and by the fitness of the immune system, as discussed next.
The crucial role of the immune system
The completion of the senescent programme, the kill-it step 
(Fig. 2), requires the effective and timely cooperation of the 
immune system, and possibly, this is the most important fac-
tor for determining a successful resolution (Fig. 1). Immune 
surveillance of senescent cells is mainly carried out by natu-
ral killer (NK) cells, macrophages and T cells. NK cells 
target senescent cells via the receptor NKG2D binding to the 
ligands MICA and ULBP2 on the surface of senescent cells, 
and mediate their killing by the release of perforin and gran-
zymes [84, 85].  CD8+ and  CD4+ T cells are also involved in 
the elimination of senescent cells [86, 87]. The completion 
of the clearance to favour resolution requires the involve-
ment of phagocytic cells like macrophages. Enrichment of 
F4/80+ cells was detected around areas of senescent cells in 
postpartum uterus, and their depletion caused enlargement 
of those areas [88]. In addition, it was found that mono-
cytes/macrophages were required to complete the clearance 
of senescent hepatocytes after  CD4+ T cells activity [86]. 
Macrophage plasticity may also be important and can be 
influenced by the SASP. Senescent stellate cells were shown 
to induce macrophage class-switch towards M1 phenotype 
favouring their clearance, while proliferating cells induced 
an M2 phenotype creating a tumour-promoting environment 
[89]. This co-existence of non-senescent cancer cells seems 
to be essential in the final outcome of senescence as it has 
also been shown that non-senescent hepatocellular carci-
noma cells block the maturation of  CCR2+ myeloid precur-
sors preventing the clearance of senescent cells, favouring 
tumour growth [79].
The impact that organismal ageing exerts on the effi-
ciency of the immune system and its surveillance capacity 
seems to drive the persistence of senescent cells within tis-
sues and consequently their pathogenic effects. In a bleomy-
cin model, it has been shown that senescent cell turnover can 
take from days in young mice to weeks in old animals [50], 
and that the reduced  CD8+ T cell cytotoxic activity associ-
ated with age accelerates the accumulation of senescent cells 
[51]. However, inefficient clearance is not always due to an 
intrinsic defect in immune cells. For the immune system to 
find senescent cells, these have to be discoverable. Senes-
cent cells can play ‘hide and seek’ and evade the immune 
system by the expression or release of certain mediators. 
The mechanisms for clearance of apoptotic cells are well 
understood and require the release of find-me signals (e.g. 
S1P, CX3CL1), with a balanced expression of eat-me (e.g. 
phosphatidylserine, calreticulin) and do not-eat-me signals 
(e.g. CD47, CD31, PAI-1) [90, 91]. These signals have been 
extensively investigated and exploited to promote resolution 
of inflammation [92–94]. Although these signals are not so 
well understood for senescent cells, several do not-eat-me 
signals have been reported, like expression of checkpoint 
molecule HLA-E, which blocks NKG2D-mediated cyto-
toxic response by NK and  CD8+ T cells [87], or expression 
of decoy receptor 2, Dcr2, which inhibits the activation of 
death receptors 4 and 5 [85]. Other mechanisms may exist 
that render senescent cells immunologically cold and appro-
priate immune recognition signals are necessary to gener-
ate a response by immune cells. Moreover, the expression 
of these signals may depend on the influence of context-
specific microenvironments. On the other hand, post-trans-
lationally modified vimentin has been proposed as an eat-me 
signal for senescent cells [95]. Little is known about whether 
additional eat-me signals exist in senescent cells, or if the 
senescent programme evolved to be coupled to subsequent 
apoptosis, relying then on the typical apoptosis eat-me sig-
nals to complete clearance.
Not all senescent cells are created equal
To produce a unified classification of senescence has proven 
difficult as multiple criteria could be applied: replica-
tive or premature, presence or absence of DNA damage, 
intrinsically or extrinsically induced, damage-induced or 
developmentally programmed, and more. It is striking how 
a rather simple phenomenon, cell cycle arrest, can gener-
ate a vast diversity of cellular states. Multiple stimuli can 
result in senescence via multiple mechanisms, in multiple 
cell types, resulting in multiple SASP types, and multiple 
outcomes. Senescence heterogeneity occurs at many levels 
with implications in disease phenotypes, potential therapeu-
tic approaches, in the way we conduct research and in the 
interpretation of results.
Several and diverse types of stimuli can induce senes-
cence, including telomere attrition [5], oncogenic transfor-
mation [21], PTEN loss [96], mitochondrial dysfunction 
[97], cytosolic DNA [98], chemicals and genotoxic drugs 
[99, 100], disturbed blood flow [101], ultraviolet radia-
tion [102], cell fusion [103], proteasome inhibition [104], 
or by melanocortin receptor 1 agonism [34]. The mecha-
nisms by which senescence is executed also differ. While 
p16 (CDKN2A) plays a prominent role in oncogene-induced 
senescence [21], it is mainly p21 (CDKN1A) that mediates 
senescence during telomere loss [105] and embryonic devel-
opment [11]. In hepatic tumour cells, however, it was shown 
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that cells can evade senescence even when p16, p19, p21 
and p53 are all expressed [106]. Moreover, the pro-senes-
cence effect of p16 in human cells is more prominent than 
in mouse cells [107]. The DNA damage response mediates 
senescence as a result of telomere loss [105, 108] and in 
certain types of oncogene senescence [3], but not when 
senescence is elicited by mitochondrial dysfunction [97] or 
by developmental cues [11].
Heterogeneity in the SASP composition is also well 
documented. Although in general terms, the SASP is typi-
cally described as pro-inflammatory, there are many exam-
ples in which this is not the case. Senescence induced by 
mitochondrial dysfunction in human fibroblasts lacks IL-
1-related cytokines [97], and senescence induced by ectopic 
expression of p16 does not increase typical SASP cytokines 
like IL-6, IL-8 or CXCL-1 [109]. Senescence induced by 
proteasome inhibition in lung fibroblasts also leads to a pre-
dominantly non-inflammatory secretome [110]. In addition, 
atypical non-inflammatory SASP is also associated with 
senescence induction by certain drugs, like treatment with 
doxorubicin on endothelial cells [111] and  MC1-selective 
ligands on synovial fibroblasts [34]. It has been suggested 
that persistent DNA damage mediates cytokine secretion by 
senescent cells [112] via the activation of NF-κB [113]. It 
might then be plausible that in those types of senescence 
processes lacking a DDR response, the resulting SASP will 
not be pro-inflammatory. It remains to be known which 
scenario will be more favourable to achieve resolution: a 
pro-inflammatory SASP able to call the immune system to 
induce clearance, or a silent SASP that does not cause dam-
age to the surrounding tissues but may delay clearance.
The sensitivity of cells to senolytics is also heterogene-
ous. Senolytics are drugs that induce lysis of senescent cells 
and are under investigation as potential therapies for cancer, 
ageing and other conditions. However, depending on the type 
of senescence, some senolytics may be more effective than 
others. The senolytic Bcl-2 inhibitor ABT-263, navitoclax, 
was effective in inducing apoptosis in murine embryonic 
fibroblasts [114], but ineffective in murine sarcoma cells 
overexpressing p16 [115]. Navitoclax was also ineffective in 
inducing cell death in melanoma cells, an effect attributed to 
increased levels of anti-apoptotic MCL-1. Interestingly, co-
administration with the MCL-1 inhibitor S63845 markedly 
sensitized the cells to death by navitoclax [116].
One of the major implications of this multi-level hetero-
geneity is the lack of universal markers of senescence, which 
impacts scientific research in particular when comparing dif-
ferent studies. Multiple markers have been described, some 
of which are more common than others among the different 
types of senescence and are typically used in senescence 
research (Fig. 5). The most frequently used include the over-
expression of cyclin inhibitors, detection of β-galactosidase 
reflecting lysosomal expansion, decrease of proliferation 
rate, detection of heterochromatin foci or markers of DNA 
damage and release of pro-inflammatory cytokines. How-
ever, as previously discussed, these features are not always 
present. Other markers have also been described in specific 
types of senescence like lamin B1 loss in HCA2 fibroblasts 
[117], MGST1 in COPD-derived fibroblasts [118], β3 inte-
grin in primary fibroblasts [119] and WNT16B during rep-
licative senescence in fibroblasts [120]. If we accept the 
definition of cellular senescence as cell cycle arrest with 
maintained cellular growth, as a minimum, measurements or 
markers indicative of decreased proliferation (cell number, 
proliferation marker Ki67, cell cycle phases, etc.), accom-
panied with markers indicative of increased growth or meta-
bolic activity that distinguishes senescence from other cell 
arrested cellular states (e.g. increased cell size, lysosomal 
expansion reflected in β-galactosidase or lipofuscin content, 
etc.) should be used to determine the presence of senescence 
(Fig. 5). Other common hallmarks of senescence, however, 
may require the analysis of specific biomarkers, like par-
ticular SASP components [4, 113, 121], presence of DNA 
damage or involvement of specific CDK inhibitors. This may 
help to define the specific type of senescence as they tend 
to be context-dependent. This approach, while feasible dur-
ing in vitro studies, presents difficulties in detecting senes-
cence in vivo. Typically, detection of cell cycle inhibitors, 
β-galactosidase in tissue sections or whole organs, lipofus-
cin staining or reporter mice like the p16-3MR [32], INK-
ATAAC [122], humanised p16-luc [123] and p21-p-luc mice 
[124] are currently available.
As universal markers may not exist, the creation of a 
catalogue compiling all types of senescence, with features 
and markers characterizing each one, would represent a very 
helpful initiative. Such a resource might include sections like 
cell type affected, physiological/pathological context, induc-
ing stimulus, DNA damage involvement, participating cyc-
lin inhibitors or SASP components. Recently, the literature-
based resource SeneQuest (https ://seneq uest.net) have been 
made available to search for genes related to senescence.
Senescence in the pipeline
Opportunities for therapeutic exploitation 
of senescence
Cellular senescence offers an arsenal of potential therapeu-
tic uses: for some, its intrinsic anti-cancer properties can 
be further exploited, while for others, senescence holds the 
secrets of youth. However, the bi-directional nature of these 
options, that is promotion or elimination depending on the 
target disease, presents important challenges: what is ben-
eficial for one purpose may potentially be detrimental for 
another. The therapeutic potential of promoting, preventing, 
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Fig. 5  Hallmarks of senescence and biomarkers used in research. 
Cell cycle arrest ([122, 166]) increased cell size ([10, 166, 177]), 
lysosomal compartment expansion ([178–180]), DNA damage ([117, 
181–184]), SASP components ([4]), anti-apoptotic pathways ([185]). 
Abbreviations: Immunofluorescence (IF), flow cytometry (FC), west-
ern blot (WB), colorimetric (C), histochemistry (HC), DNA damage 
response (DDR)
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killing, modulating and clearing senescence will now be dis-
cussed (Fig. 6).
Several pro-senescence drugs are currently approved for 
the treatment of cancer, including methotrexate, etoposide, 
tamoxifen, palbociclib, doxorubicin or cisplatin, among 
many others, and generally induce senescence by a DNA-
damage-mediated mechanism or interference with cell cycle 
components, among other mechanisms [99, 100, 125, 126]. 
Side effects derived from persistent SASP or from the pro-
senescence action in off-target tissues limit their use [126, 
127]. However, the induction of senescence also represents 
an opportunity to generate new vulnerabilities in cancer 
cells. Wang et al. demonstrated that p53 mutant liver cancer 
cells made senescent by treatment with CDC7 kinase inhibi-
tors, become susceptible to senolysis by the antidepressant 
sertraline [128]. Interestingly, it has also been reported that 
p53 mutant breast cancers are resistant to chemotherapy with 
doxorubicin when co-treatment with hormone therapy is not 
used, because cells bypass apoptosis and become senescent. 
However, these p53 mutant cells rendered senescent by dox-
orubicin became sensitive to tamoxifen [129]. Hence, this 
double-hit approach suggests that induction of senescence 
followed by senolysis can enhance therapeutic efficacy in 
cancer. Induction of senescence to favour wound healing 
and induce resolution of fibrosis or chronic inflammatory 
conditions like rheumatoid arthritis may require less toxic 
Fig. 6  Potential therapeutic strategies based on senescence. Senescence can be targeted from multiple angles and has the potential to benefit 
multiple therapeutic indications. Abbreviations: activator/agonist ( ⊕), inhibitor/antagonist ( ⊖), overexpression (↑)
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approaches like the recently discovered pro-senescence 
activity of  MC1-selective agonists [34], acting via the acti-
vation of a highly druggable GPCR which ligands have 
been shown to be safe in clinical trials. Other pro-senes-
cence approaches reported include the inhibition of aurora 
kinases [130], Shp2 inhibitors [131], suicide gene therapy 
[115], MDM2/p53 interaction inhibitors [132], treatment 
with CCN1 protein [30] or interleukin 22 [133]. Interest-
ingly, it was also shown that reprogramming approaches by 
ectopic expression of OSKM or Yamanaka factors (OCT4, 
SOX2, KLF4, MYC) to induce pluripotent stem cells (iPS) 
is strongly associated with induction of senescence where 
senescent cells create a tissue context involving IL-6 that 
favours OSKM-driven reprogramming in surrounding cells 
[134].
Complete suppression of senescence will invariably pro-
mote cancer development. However, there might be ways to 
prevent certain types of stress-related senescence by reduc-
ing the relevant stress signals. This approach is based on the 
information theory of ageing, suggesting that the accumula-
tion of damage at the cellular level decreases cellular repair 
mechanisms, leading to decreased functionality of the whole 
organism. Ageing produces accumulation of DNA instability 
leading to re-distribution of the epigenetic regulators sirtuins 
to engage into repair mechanisms as a survival circuit, which 
is accompanied by disengagement of other cellular activi-
ties. This epigenetic noise (or information loss) caused by 
exhaustion of the survival mechanism, leads to loss of cel-
lular identity terminating in senescence. Although this the-
ory, so far, has only been fully demonstrated in yeast [135, 
136], substantial evidence suggests a mayor role of sirtuins 
in eukaryotic cells senescence too. Sirt1 prevents telomere 
shortening in mice [137], while Sirt6 overexpression pre-
vented replicative senescence in human cells [138]. Caloric 
restriction, by inducing sirtuins and enhancing DNA repair 
mechanisms, can reduce senescence burden in ageing and 
extend lifespan [139]. Caloric restriction can be mimicked 
with sirtuin-activating compounds (STACs) such as resvera-
trol, fisetin, or  NAD+ precursors, which extend the lifespans 
of yeast, mice and humans [140–142]. Consistently, it has 
been shown that the inhibition of Sirt1 promotes premature 
senescence in mouse fibroblasts [143]. However, sirtuin 
inhibitors like sirtinol [144] present anti-senescence activ-
ity, suggesting that further research is needed to fully elu-
cidate the role of sirtuins, or their targeting, in senescence. 
Indeed, it has been suggested that the dual outcome of sir-
tuin inhibition might depend on p53 status [145]. STACs act 
by activating AMPK which in turn inhibits mTOR. Hence, 
AMPK activators like metformin and mTOR inhibitors like 
rapamycin also prevent senescence and ageing [142, 146]. 
Inhibition of SIRT1 was also achieved by expression of the 
microRNA miR-34a, reducing senescence in human adipose 
tissue-derived mesenchymal stem cells [147].
The elimination of senescent cells using senolytics is 
being intensively investigated for applications in cancer, age-
ing and facilitation of resolution in fibrosis. Hence, under the 
right context, senolytics may also act as pro-resolving drugs. 
Senolytics aim to induce death in senescent cells without 
affecting proliferating or quiescent cells, by targeting a 
wide range of vulnerabilities existing specifically in senes-
cent cells. These include the increased expression of BCL 
anti-apoptotic proteins (navitoclax and other BH3-mimet-
ics), the PI3K/AKT pathway (quercetin), ephrin receptors 
(dasatinib), lysosomal V-ATPase (bafilomycin A1, concana-
mycin A), Na + /K + ATPase (cardiac glycosides), MDM2/
p53 interaction (UBX0101), mTOR pathway (sertraline), 
oxidation resistance 1 (piperlongumine), USP7 protease 
(P22007), urokinase-type plasminogen activator receptor 
(CAR-T cells) and bromodomain and extra-terminal (BET) 
family proteins [66, 128, 148–154]. General cytotoxic drugs 
like the antibiotic duocarmycin can also be converted into 
senolytics by addition of a galactose motif, creating a pro-
drug that is preferentially cleaved under high β-galactosidase 
expression, producing a targeted-delivery system for senes-
cent cells [155]. Other antibiotics like azithromycin and 
roxithromycin have shown preferential cytotoxic activity 
in senescent fibroblasts [156], although the exact mecha-
nism has not been reported. As previously discussed, dif-
ferent types of senescence display different sensitivities to 
senolytics.
A fourth type of approach to targeting senescence consists 
of using drugs that modulate the composition of the SASP, 
commonly termed senomorphics. The search for senomor-
phics has been focused on the discovery of drugs that reduce 
the pro-inflammatory activity of the SASP. For example, 
NF-κB inhibitors like apigenin or glucocorticoids can reduce 
the pro-inflammatory nature of the SASP [157, 158], as well 
as p38 inhibitors and JAK inhibitors, like SB203580 mol-
ecule and ruxolitinib, respectively [159, 160]. The natural 
compound rapamycin, via inhibition of mTOR, also modu-
lates the composition of the SASP towards a less damag-
ing secretome, and has shown to increase lifespan in mice 
[161, 162]. A senomorphic therapy is aimed at reducing the 
detrimental effects of a persistent SASP without the need 
of eliminating the senescent cells, which might be more 
advantageous than a senolytic as it may allow senescent 
cells to perform their physiological and reparative actions, 
without fuelling further inflammatory processes; however, 
this view needs to be corroborated. Therapeutic areas for 
potential application of senomorphics include the prevention 
of ageing associated pathologies, reduction of inflammatory 
pro-tumour microenvironment in cancer and reduction of 
damaging SASP during fibrosis.
Clearance of senescent cells can also be promoted thera-
peutically to facilitate their removal from tissues. The pro-
tumorigenic effect of senescent cells derives from their 
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persistence in tissues after containing the oncogenic dam-
age. Thus, strategies that promote the surveillance capac-
ity of immune cells may contribute to tumour regression. 
Ruscetti et al. demonstrated that treatment with palboci-
clib induced senescence in pancreatic cancer with a pro-
angiogenic SASP, which favoured the recruitment of  CD8+ 
T cells. These recruited cells showed signs of exhaustion but 
the combination of pro-senescence therapy with blockade of 
PD-1 checkpoint triggered T cell anti-tumour activity [19]. 
Hence, therapies to enhance clearance by immune system 
require not only the recruitment of appropriate cells, but 
also to ensure that their cytotoxic activity is intact. In addi-
tion, as discussed above, senescent cells need to be visible to 
the immune system to trigger their phagocytosis. Enhance-
ment of apoptotic cell clearance can be achieved for exam-
ple, by targeting the eat-me signal phosphatidylserine with 
a modified annexin A5 that interacts with αvβ3 receptors 
on the surface of macrophages [92]. This approach not only 
favoured resolution but it also induced the release of anti-
inflammatory IL-10 by the phagocyte. This switch from 
pro- to anti-inflammatory signals during efferocytosis has 
been referred to as “tolerate me” signals [163]. Whether a 
similar non-phlogistic mechanism occurs during senescent 
cell engulfment remains to be studied. Another example of 
efferocytosis enhancement includes the matricellular protein 
CCN1, which facilitates the clearance of apoptotic neutro-
phils by a similar mechanism, bridging the apoptotic cell 
with the phagocyte [164]. Interestingly, as mentioned ear-
lier, CCN1 induces senescence during physiological wound 
healing but whether CCN1 could also act as an opsonin for 
senescent cells has not been determined. On the other hand, 
blocking the do not-eat-me signal CD47 was demonstrated 
effective in promoting phagocytosis of apoptotic cells and 
preventing atherosclerosis [165]. The identification of simi-
lar signals that selectively tag senescent cells may lead to 
similar pro-phagocytic approaches as the one already exist-
ing for apoptosis.
Finally, reversal of senescence is typically investigated 
with the aim to discover factors that mediate the irreversibil-
ity of senescence [166]. It was found that telomere-induced 
senescence may be reversed by p53 or Rb inactivation if 
p16 is expressed at low levels [167], indicating the require-
ment of high levels of p16 to sustain the irreversible state. 
Non-replicative senescence in  CD4+ memory T cells showed 
dependence on the p38 pathway [168]. Hypothetically, the 
reversal of senescence may benefit ageing-related patholo-
gies by enhancing immunosenescence or by replenishing 
depleted stem cell pools. However, this approach brings the 
risk to spread the damage that led to senescence induction in 
the first place. The protein Rpl1 induces the bypass of repli-
cative senescence but also contributed to transformation in 
 rasVal12 mutant cells [169]. It is also believed that the trans-
formation from nevi (senescent melanocytes) to melanoma 
occurs when senescent cells regain the ability to proliferate 
by acquiring additional abnormalities, hence reverting their 
senescent status [170].
Ongoing approaches in clinical development
Despite all the existing challenges, multiple clinical inves-
tigations with senescence-related approaches are currently 
undergoing. We identified 250 clinical trials registered at 
the World Health Organization repository with the majority 
(180) being interventional (Fig. 7, Table 1).
Unity Biotechnology Inc. has completed a phase I pla-
cebo-controlled trial where the primary outcome was to 
address the safety and tolerability of a single intra-articular 
injection of UBX0101, monitoring the incidence of seri-
ous and non-serious adverse events in knee osteoarthritis 
(NCT03513016). The compound is reported by the com-
pany as an inhibitor of the interaction between MDM2/
p53, and has displayed senolytic properties in pre-clinical 
research [171]. A phase II trial with ~ 180 participants is 
currently ongoing to investigate the efficacy of a single dose 
on osteoarthritis pain score (NCT04129944). A small pilot 
study in five participants with Alzheimer’s disease is being 
conducted to assess brain penetrance of the senolytic com-
pounds dasatinib and quercetin (NCT04063124). Another 
trial has investigated the efficacy of these two senolytics, 
given orally, in eliminating senescent cells in chronic kidney 
disease patients (NCT02848131). Results for this trial, led 
Fig. 7  Clinical trials related to senescence. Information retrieved 
from the WHO International Clinical Trial Registry Platform in July 
2020 using the search terms: senescence, senescent, senolytics, seno-
lysis, senomorphic, senotherapy, senotherapeutic. This figure shows 
the classification of the trials according to different criteria: observa-
tional/interventional, whether they are actively recruiting or not, and 
the trial phase. Of the 180 interventional studies identified, 41 were 
actively recruiting. Of the 69 observational studies, 27 were actively 
recruiting. A selection is shown in Table 1
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by Mayo Clinic, have been published [171], reporting signif-
icant decreases in senescent cell burden. Oral administration 
of fisetin, a sirtuin activator but also reported as senolytic, is 
being trialled in ~ 70 patients with osteoarthritis to address 
safety (NCT04210986). Observational studies on the role 
of senescence in several diseases are also being conducted, 
including COPD, diabetes, wound healing, complicated 
pregnancies and circulatory shock (Table 1).
Challenges in senescence research and potential 
therapies
While reviewing the recent advances in senescence research 
and directions towards potential clinical applications, we 
identified a number of challenges, gaps and research paths 
that may help advance the field of senescence and accelerate 
its successful translation into clinics.
We now know that senescence comes in many flavours, 
induced by multiple mechanisms leading to different SASPs, 
that may, or may not, be pro-inflammatory. Senescence is 
intensively studied in the context of fibrosis where bleomy-
cin is used to induce the disease in animal models. However, 
bleomycin itself induces senescence by causing direct DNA 
strand breaks [172], suggesting that the SASP and its actions 
may greatly differ from the ones produced by endogenously 
induced senescence during would healing and fibrosis, and 
as such, results may not be extrapolatable into human dis-
ease. Fibrosis models have also been used to test senolytics 
Table 1  Clinical trials investigating senescence-related therapies
Information retrieved from the WHO International Clinical Trial Registry Platform on July 2020 using the search terms: senescence, senescent, 
senolytics, senolysis, senomorphic, senotherapy, senotherapeutic. A selection from 250 trials identified is shown
Trial ID Condition Intervention Sponsor
NCT02102724 HIV-Related Immune Senescence Fish oil omega-3 Rush University
NCT03100799 Biomarkers of Senescence in Osteo-
arthritis of the Knee
Arthroscopy, Arthrocentesis, MRI Unity Biotechnology, Inc
NCT03338985 Role of Senescence in of Endome-
trial Cancer
Genetic analysis CHU de Reims
NCT04113122 Senescence After Chemotherapy for 
Testicular Cancer
Skin, fat biopsy University Medical Center Groningen
NCT03513016 Phase I Osteoarthritis of the Knee UBX0101 Unity Biotechnology, Inc
NCT03353597 Phase I/II Reversing Epigenetic & Senescence 
by Transfusing Young Plasma
Plasma Transfusion Chandra Duggirala
NCT04063124 Phase I/II Progression of Alzheimer’s Disease Dasatinib, Quercetin University of Texas
NCT04210986 Phase I/II Osteoarthritis Cartilage Degenera-
tion
Fisetin Steadman Philippon Research 
Institute
NCT02533180 Phase II Donor Specific Immune Senescence 
and Exhaustion—Liver Transplan-
tation
Immunosuppression withdrawal NI of Allergy and Infectious Diseases
NCT04313634 Phase II Skeletal Health in Older Humans Dasatinib, Quercetin, Fisetin Sundeep Khosla
NCT02848131 Phase II Chronic Kidney Disease Dasatinib, Quercetin Mayo Clinic
NCT00461695 Phase IV Persistent CMV infection on 
Immune Senescence
Vaccination against TBEV University of Zurich
NCT01827462 Phase IV Immune Responses—Influenza 
Vaccine
Inactivated vaccine Stanford University
EUCTR2012-003,987–34-BE Senescence markers—Kidney Trans-
plantation
Metformin UZ Leuven
KCT0003477 Phase III Senescence in type 2 diabetes with 
Hypercholesterolemia
Rosuvastatin, ezetimibe Chungnam National University 
Hospital
NCT02368821 Senescence in Placenta from Com-
plicated Pregnancies
Observational Meir Medical Center
JPRN-UMIN000016565 Cellular Senescence in COPD Observational Tohoku University
JPRN-UMIN000040058 Senescence cell in Diabetic Hand 
Syndrome
Observational Nagoya University,
NCT02755584 Senescence During Wound Healing Observational National Institute on Aging
NCT03559569 Senescence in Circulatory Shock Observational University Hospital, Strasbourg
ChiCTR2000031492 Osteoarthritis After Anterior Cruci-
ate Ligament Tear
Observational Shanghai Jiaotong University
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and generally, when such treatments improve fibrosis, it 
is believed that senescent cells were the pathogenic cells. 
However, as Lagares et al. demonstrated, senolytics can also 
target and kill activated (i.e. non-senescent) myofibroblasts 
[47], which are major drivers of fibrosis. Therefore, the pro-
tective effects of senolytics in fibrosis should not be directly 
attributed to the elimination of senescent cells without per-
forming more in-depth investigations.
Pro-senescence therapies are currently used to treat sev-
eral forms of cancer. The major obstacles derive from the 
induction of senescence in off-target tissues, which may pro-
mote their premature ageing. Hence, selective and targeted 
senescence to cancer cells would be preferred. The group of 
Bernards et al. is working in that direction by performing 
screenings of pro-senescence targets in cancer cells. They 
identified not only molecules that induce senescence specifi-
cally in liver cancer cells, but, following a second screen-
ing, they also found specific senolytics which favour their 
elimination [128]. This is an excellent example of the inte-
gration of a pro-senescence followed by senolytic approach 
to ensure completion of the senescence programme, which 
they call the ‘one-two punch’ approach. Certain types of 
cancer are actually derived from mutations in genes related 
to senescence, like CDKN2A, inducing malignancy due to 
their ability to bypass senescence [24]. A better understand-
ing of alternative routes to induce senescence may help to 
design novel therapies for those cancers.
Anti-senescence approaches are based on preventing the 
build-up of informational noise caused by cellular stress that 
leads to senescence. It has been reported that inhibitors of 
mTOR like rapamycin have anti-senescence, senolytic and 
senomorphic activity with potential to reduce age-related 
pathologies. However, rapamycin may also prevent onco-
gene-induced senescence by preventing up-regulation of 
p53, hence impairing our major endogenous anti-cancer 
mechanism from acting [96]. These potential detrimental 
actions require further investigation to ensure the safety of 
such approaches.
Some strategies focus on identifying common targets of 
senescent cells to develop broad-spectrum senolytics [149, 
154, 155]. These can be very useful as research tools and 
will allow the comparison of different studies if all senescent 
cells, regardless of their type and context, respond to the 
same senolytic. However, selective senolytics for each type 
of senescence, and possible each cell type, may be more 
beneficial for therapeutic applications than a one-size-fits-all 
approach. For example, we may need to favour the elimi-
nation of senescent cells from a tumour while preserving 
senescent cells physiologically dealing with wound heal-
ing. This may reduce the therapeutic indications available 
for such drugs, but might provide a more balanced risk/
benefit profile. However, this will require the identification 
of specific vulnerabilities for each type of senescence. In 
addition, all animal studies with senolytics, as with all stud-
ies essentially, are performed under controlled conditions 
where mice do not suffer from additional co-morbidities, 
traumas, or wounds. It is then yet unknown how senolytics 
will perform in more real-life situations. Another challenge 
related to senolytics is that the elimination of senescent cells 
may not restore organ or tissue function if not coupled with 
pro-regeneration approaches [45]. The elimination of senes-
cent chondrocytes in osteoarthritis may help to reduce the 
sustained release of pro-inflammatory factors, but that alone 
may not lead to restoration of the chondrocyte population 
due to the intrinsic limited regenerative capability of this 
avascularised tissue. The same concept applies to fibrosis, 
where repopulation with functional parenchymal cells, not 
only elimination of senescent ones, is required for restora-
tion of tissue function. The effects of senolysis on stem cell 
exhausted tissues may not restore function.
A further challenge is that senolytics are developed under 
the assumption that the immune system may recognise 
dead senescent cells, i.e. apoptotic cells. Speculating as we 
write, it may be possible that in certain contexts, phagocytes 
might not recognize senescent or apoptotic cells, rendering 
senolysis approaches detrimental, as deficient efferocytosis 
also leads to secondary cell necrosis, which would sustain 
pro-inflammatory damage and comport failed resolution. 
Indeed, inefficient efferocytosis is associated with patholo-
gies like systemic lupus erythematosus due to genetic or 
acquired C1q deficiency [173]. How senolysis will perform 
in immunosuppressed patients also remains unknown. An 
interesting aspect of the clearance of senescent cells is that 
they are eaten alive, a process termed phagoptosis [174]. 
This may represent an opportunity for the development of 
strategies aimed at actively modulating the expression of 
surface molecules that target them for clearance, similar to 
approaches already under investigation that actively modu-
late the composition of the SASP. This is possible, because 
it is known that the SASP can be modulated without affect-
ing the irreversibility of cell cycle arrest, as they seem to be 
controlled by independent regulatory networks. Cell cycle 
arrest is largely dependent on p16/Rb or p53/p21 pathways, 
whilst the SASP is more dependent on NF-κB, C/EBPβ or 
mTOR pathways [175] and inhibiting the latter ones does 
not revert cell cycle arrest.
The field of ageing research is also facing the difficulty in 
running the long clinical trials that will be required to assess 
if senolytics may indeed prevent age-related diseases. To 
facilitate research, the inclusion of organismal senescence 
(essentially ageing) as a disease category in the WHO Inter-
national Classification of Diseases (ICD) has been proposed 
[176]: a major challenge, because accepting that ageing is 
a disease will have important social, political and medi-
cal implications. In the latest ICD version (ICD-11, https 
://www.icd.who.int), ‘old age’, under the code MG2A, is 
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recognised as a symptom, sign or clinical finding, not else-
where classified. Although age as a disease is difficult to 
accept by many, others are happy to conduct self-experi-
mentation by taking available senolytics and STACs like 
quercetin or resveratrol. This kind of citizen science can be 
a double-edged sword. In the field of melanocortin research, 
due to self-administration of illegal melanocortin peptides 
to boost tanning, the development of melanoma on some of 
these individuals, likely derived from their risky behaviour 
in their sun exposure, led to the wrong suspicion that mel-
anocortins may cause melanoma, a conclusion disproved in 
controlled clinical trials.
Summary
Senescence has emerged in recent years as the rising star 
among the cellular processes to target to develop innovative 
therapies due to their potential impact on diverse therapeu-
tic areas, such as cancer, fibrosis and ageing. We propose 
here the process of cellular senescence as an endogenous 
pro-resolving mechanism. If we consider their clearance 
as an integral step of the senescence programme, failure 
to complete this last step is what results in non-resolving 
inflammation. Furthermore, we reason on how senescence 
is a highly heterogeneous phenomenon and we suggest that 
a precise definition of context will benefit our understand-
ing and enable reliable and meaningful comparison across 
different studies. Senescence can be targeted from multiples 
angles (promotion, prevention, killing, modulation, clear-
ance) and it is important to consider the context to determine 
what, when and how we should target senescence. Whether 
beneficial or detrimental, this cannot be decided without tak-
ing the context into account.
Senescence passes the appraisal, with the set objectives 
of (i) improving detection strategies, (ii) consideration of 
contextual aspects to decide beneficial/detrimental role, (iii) 
understanding better how the process of clearing occurs and 
could be modulated, (iv) creation of repositories compil-
ing features of all types of senescence (cell type, context, 
pathways, SASP, biomarkers), and (v) development of 
more targeted approaches for specific pathological situa-
tions. Neither zombie cells nor regenerative powers, deci-
phering the process of senescence has a great potential to 
improve human health, potential reflected in the prominent 
presence of senescence approaches currently under clinical 
development.
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